ArticleAntimicrobial agents and chemotherapy2026
Multidimensional assessment of in-host fitness costs of echinocandin resistance in the opportunistic fungal pathogen
Amir Arastehfar, Farnaz Daneshnia, Hrant Hovhannisyan, Nathaly Cabrera, Sebastian Jusuf, Mostafa Salehi, Michael K Mansour, Toni Gabaldón, Erika Shor, David S Perlin
Abstract read
In one paragraphArticle in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Amir Arastehfar *Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-4361-4841 Farnaz Daneshnia *Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Hrant HovhannisyanLife Sciences Programme, Supercomputing Center (BSC-CNS), Barcelona, Spain.
Nathaly CabreraCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Sebastian JusufDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Mostafa SalehiDepartment Industrial Engineering Faculty of K.N, Toosi University of Technology, Tehran, Iran.
Michael K MansourDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Toni GabaldónLife Sciences Programme, Supercomputing Center (BSC-CNS), Barcelona, Spain.
David S PerlinCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0000-0002-1268-5524 Funding
Critical Factors Influencing Echinocandin Resistance in CandidaglabrataR01AI109025 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI PERLIN, DAVID S · 2014 to 2025
$9.8MNIAID NIH HHS R01 AI109025NIH HHS R01AI109025
6 · The paper itselfAbstract
Host stresses are often considered a major barrier against the emergence of echinocandin resistance (ECR) in prominent infecting organisms like
Indexed as
Antifungal AgentsCandida glabrataCandidiasisDrug Resistance, FungalEchinocandinsFungal ProteinsGlucosyltransferasesAnimalsHumansHydrogen PeroxideMacrophagesMiceMutationNeutrophilsOxidative StressAntifungal AgentsEchinocandinsFungal ProteinsGlucosyltransferasesHydrogen PeroxideCandida glabratacell wallechinocandinechinocandin resistancefitness costgut colonizationintracellular replicationneutrophilsystemic infection
Identifiers
PMID41870047
PMCPMC13148028
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390